ArticleFrontiers in pharmacology2026
Aloe-emodin inhibits nasopharyngeal carcinoma by modulating telomerase activity involving the c-Myc/E2F1 axis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The telomerase catalytic subunit hTERT is a critical oncogenic driver in nasopharyngeal carcinoma (NPC). The specific role of aloe-emodin (AE) in regulating hTERT in NPC has not been systematically investigated. The regulatory network involving hTERT and its upstream transcription factors, c-Myc and E2F1, offers a promising therapeutic avenue. Methods: Bioinformatics was used to analyze hTERT expression and its prognostic significance in head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Molecular docking simulations were conducted to investigate the potential interaction between AE and hTERT. hTERT expression was assessed in normal nasal epithelial cells and NPC cell lines. Effects of AE on hTERT, c-Myc, and E2F1 were measured using qRT-PCR and Western blotting. Telomerase activity was evaluated through TRAP-qPCR and PAGE. hTERT was knocked down using siRNA. Cell proliferation, migration, and invasion were analyzed using CCK-8, EdU, colony formation, and Transwell assays. ROS levels were quantified using DCFH-DA staining. Results: Bioinformatics analysis revealed elevated hTERT expression in HNSC tissues and NPC cell lines Molecular docking predicted a potential interaction between AE and the catalytic pocket of hTERT. Conclusion: This study presents the first systematic validation of AE's anti-NPC effects. These include hTERT suppression, modulation of the c-Myc/E2F1 network, and induction of oxidative stress. These findings suggest a potential therapeutic target and strategy for NPC. The results support the clinical translation of AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.